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ACC Acetyl-CoA carboxylase 
ADC  Adenocarcinoma 
AMPK AMP-dependent kinase 
ATF3 Activating transcription factor 3 
BSA Bovine serum albumin 
CAMK2A Calcium/calmodulin dependent protein kinase II alpha 
cDNA Complementary DNA 
DMED Dulbecco’s Minimum Essential Medium 
DNMT DNA methyltransferase 
dNTP deoxyribose nucleoside triphosphate 
EED Embryonic ectoderm development 
EZH2 Enhancer of zeste homologue 2 
FBS Foetal bovine serum 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GFP Green fluorescent protein 
HES1 Hairy and enhancer of split-1 
H3K27ac Histone 3 lysine 27 acetylation 
H3K27me3  Histone 3 lysine 27 trimethylation 
JMJD3 Jumonji domain-containing protein D3 
KDM6A/B Lysine demethylase 6A/B 
KLF4 Krüppel-like factor 4 
KRAS Kirsten rat sarcoma viral oncogene homolog 
LKB1 Liver kinase B1 
lncRNA Long non-coding RNA 
MEF Mouse embryonic fibroblast 
NSCLC Non-small cell lung cancer 
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OAZ1 Ornithine decarboxylase antizyme 1 
p-ACC Phospho-ACC 
p-AMPK Phospho-AMPK 
PBS Phosphate-buffered saline 
PcG Polycomb group proteins 
PIM1 Proto-oncogene serine/threonine protein kinase Pim-1 
PJS Peutz-Jeghers syndrome 
PRC1/2 Polycomb repressive complex 1/2 
PRKAA/B/G Protein kinase AMP-activated catalytic subunit alpha/beta/gamma 
RbAp46/48 Retinoblastoma protein associated protein 46/48 
RT-qPCR Real time quantitative polymerase chain reaction 
SCC Squamous cell carcinoma 
SCLC Small cell lung cancer 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SOX2 Sex determining region Y box 2 
SUZ12 Suppressor of zeste 12 homolog 
TBS Tris-buffered saline 
Thr Threonine 
TP53 Tumour protein P53 
UTX Ubiquitously transcribed tetratricopeptide repeat X chromosome 










Lung cancer is one of the most common and deadliest cancers worldwide, but the mechanisms 
behind different types of lung cancer are still poorly understood. Non-small cell lung cancer makes 
up 80% of lung cancers, and some epigenetic mechanisms have been proposed for it. Epigenetic 
modifications are a way of influencing the expression of genes by inhibition or activation. PRC2 is an 
epigenetic modulator that catalyses the formation of methyl groups on histone 3 lysine 27, which is 
an epigenetic mark with repressive nature. PRC2 has been proposed to be downstream of AMPK, 
an energy sensor of the cell, which is phosphorylated by LKB1 under energy stress conditions. 
Inactivating mutations in LKB1 are known to cause and worsen non-small cell lung cancer, and the 
overexpression of EZH2, the catalytic subunit of PRC2, has similar effects. Therefore, establishing a 
novel downstream mechanism linking LKB1, AMPK, and PRC2 together could explain one 
mechanism for NSCLC tumorigenesis. Changes in metabolism are a feature of cancer cells, and this 
pathway could also link energy stress and cancer together.  
Mouse embryonic fibroblast and H358 cell lines overexpressing wild type EZH2, mutant EZH2 and 
GFP were generated and treated with the glycolysis inhibitor 2-deoxyglucose to study the effects of 
energy stress. Levels of histone methylation and phosphorylation statuses of AMPK and its 
downstream target ACC were assessed with Western blotting, and expression levels of potential 
PRC2 target genes with RT-qPCR. The study setting proved to be functional for the response of AMPK 
to energy stress conditions, as both AMPK and ACC were phosphorylated in the presence of 2-DG. 
In mouse embryonic fibroblasts, PIM1 showed different gene expression with wild type and mutant 
EZH2, suggesting that its activation would be regulated through the phosphorylation of the T311 
site of EZH2 during energy stress.   
The results from histone methylation statuses did not follow the hypothesis, possibly because of the 
lack of specificity of detecting global H3K27me3. Other target genes besides PIM1 in MEFs did not 
show significant changes in expression level. Considering that the incorporation of the mutant EZH2 
into PRC2 complexes was not validated, additional research would be needed to confirm or deny 







Non-small cell lung cancer 
Cancer causes the second most deaths worldwide, and lung cancers are among the most common 
cancers both in men and women. One-quarter of all cancer deaths are due to lung cancer, and at 
19%, lung cancer still has the lowest 5-year survival rate across all cancers (Siegel et al. 2019). 
Therefore, there is a need to find possible drug targets and increase the understanding of the 
mechanisms behind lung cancer.  
This thesis focuses on non-small cell lung cancer (NSCLC), which accounts for 80% of lung cancers. 
NSCLC consists of adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Known 
causes that contribute to the rise of lung cancer include tobacco smoke, ionising radiation, and viral 
infections, but the mechanisms are not yet well established (Esposito et al. 2010). Many 
mechanisms behind cancer and NSCLC can be attributed to epigenetics, including the mechanism 
that will be studied in this thesis. 
 
Epigenetics 
Epigenetics is broad field of study that was initially used to explain the hereditary phenomena that 
could not be explained by basic genetics. It has been studied intensively in the last decades, as it 
helps to explain the gap between genotype and phenotype. With epigenetic modifications, it is 
possible to change the way genes are expressed without changing the nucleotide sequence of the 
genome. The epigenome is semi-dynamic, meaning that environmental factors can change it, but 
some of those changes are heritable. Epigenetic modifications include DNA methylation, histone 
variants, noncoding RNA, and chromatin modifications (Goldberg et al. 2007), which will be 
discussed below. 
DNA methylation 
DNA methylation is found on cytosine residues of CpG islands and its function is related to 
transcriptional repression. CpG islands are regions of the genome that have exceptionally high 
amounts of cytosine and guanine nucleotides (Goldberg et al. 2007). The methyl group is covalently 
attached to the 5’ position of the cytosine by methyl transferases such as DNMT3A, DNMT3B and 
DNMT1, making it a 5-methylcytosine. DNA methylation silences genes, and in fact most 
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transcriptional silencing of human genes occurs via DNA methylation. DNMT3A/B carry out de novo 
methylation, and DNMT1 conserves methylation patterns across cell divisions. This enables for the 
methylation pattern of the genome to be both dynamic and heritable, as environmental cues drive 
new methylation and it can be passed on in cell divisions (Mazzio et al. 2012). 
Histone variants 
Genomic DNA resides inside the mammalian cell nucleus, packaged into units called nucleosomes. 
A core nucleosome contains a histone octamer and DNA wrapped around it. The histone octamer is 
composed of two of each histone proteins H2A, H2B, H3 and H4. Linker histone H1 stabilises core 
nucleosomes into higher order structures, which makes the DNA 30 to 40 times more compact 
(Luger et al. 1997). There are several different histone variants, and their variation has an impact on 
epigenetics. Although nucleosomes are tightly packed, their function can be both activating and 
deactivating to gene expression, mostly through post-translational modifications on histone amino 
acid residues (Kimura 2013). 
Non-coding RNA 
Although non-coding RNAs (ncRNAs) were thought to be non-functional for a long time, numerous 
studies have proven them to be important regulators of gene transcription and translation. Long 
non-coding RNAs (lncRNAs) have been found to participate in the silencing of genes and are thus 
considered to constitute an important epigenetic mechanism. For instance, lncRNAs regulate 
transcription through epigenetic modifications by interfering with chromatin remodelling 
complexes such as the Polycomb repressive complexes PRC1 and PRC2. An example of an important 
lncRNA is the silencing of the inactive X chromosome, which is mediated through the expression of 
X-inactive specific transcript (XIST) (Saxena et al. 2011). 
Chromatin modifications 
Histone modifications are covalent additions to the N-terminal tail of the histone. These changes 
alter the charge of the tail residues and change the conformation of the histone and its affinity to 
DNA and other chromatin-binding molecules. The number of different histone mark combinations 
is extremely high, as modifiable amino acid residues include lysine, serine, tyrosine and arginine, 
and possible modifications include methylation, acetylation, phosphorylation, ubiquitination, 
biotinylation, sumoylation and proline isomerization (Mazzio et al. 2012). Abbreviation are 
commonly used for histone modifications, following the pattern of first the histone, then the amino 
6 
 
acid residue, and last the modification. For example, H3K27me3 stands for histone 3 lysine 27 
trimethylation.  
Although not all histone marks can be linked to a specific function, methylation and acetylation 
patterns of lysine residues of histone H3 can usually give reliable information about the 
transcriptional activity of the gene in question. The methylation status of lysine residues can be 
mono-, di- or trimethylation, and it cannot coexist with acetylation on the same lysine. The effect of 
methylation on H3 is variable, the effect of the methylation depending on the lysine residue and the 
methylation level. Specific histone modifications can still generally be linked to either gene 
activation or repression (Kimura 2013).  
Trimethylation of histone 3 lysine 27 is a mark associated with gene repression and it is often found 
in silenced chromatin such as the inactivated X chromosome (Nozawa et al. 2013). H3K27me3 is 
catalysed by the Polycomb repressive complex 2 (PRC2), a protein complex that contains the 
methyltransferase EZH2 (Margueron et al. 2011). Demethylation of H3K27me3 is done by 
KDM6A/UTX and KDM6B/JMJD3 (Sen et al. 2008). Abnormal regulation of both the 
methyltransferase and demethylases are associated with cancer (Albert et al. 2010; Pedersen et al 
2010).  
 
Polycomb group proteins 
Polycomb repressive complex 1 and 2 (PRC1/2) are complexes formed by Polycomb group proteins 
(PcG). PcG proteins are associated to silent chromatin states and their counterpart Trithorax group 
proteins (TrxG) are associated to active chromatin states (Schuettengruber et al. 2007). PcGs are 
important gene regulators at all stages of cell development and are major regulators of cell identity. 
Activity of some PcG members can extend the lifespan of epithelial cells by inducing telomerase 
activity, while some control cellular proliferation and tumorigenesis. This highlights the importance 
of epigenetic control during different stages of development (Ringrose et al. 2004). 
In mammals, PRC2 is composed of its core components EZH2, EED, SUZ12 and RbAp46/48 
(Schuettengruber et al. 2007). PRC2 is a methyltransferase that catalyses the mono-, di-, and 
trimethylation of lysine 27 of histone H3. It is a basic epigenetic function that maintains gene 
expression patterns in normal cells, and is involved in differentiation, proliferation and maintaining 
cell identity, among others (Laugesen et al. 2019; Margueron et al. 2011). The trimethyl mark 
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H3K27me3 made by PRC2 has been studied the most, and it is widely accepted as a mark of gene 
repression (Laugesen et al. 2019). PRC2 catalyses the formation of the methylation marks through 
its catalytic subunit, the methyltransferase Enhancer of zeste homologue 2 (EZH2). EZH2 is only 
present in cells that are actively dividing, as opposed to EZH1 which is found in both dividing and 
differentiated cells. PRC2 complexes that have EZH2 have higher methyltransferase activity than 
those with EZH1 (Margueron et al. 2011).  
The involvement of PRC2 in cancer is usually due to the dysregulated expression of its subunits, 
especially EZH2 overexpression.  Other subunits have also been found to be overexpressed in 
cancers, including NSCLC. In colorectal cancer patients, expression of EZH2, EED and SUZ12 mRNA 
was significantly increased when compared to non-cancerous mucosa tissue. Higher levels of these 
PRC2 subunits also correlated with worse prognosis and aggressive clinical behaviour (Liu Y.L. et al. 
2015). SUZ12 alone has also been suggested to be an oncogene in multiple cancers, including non-
small cell lung cancer. An increase in SUZ12 expression was found in NSCLC, and it was suggested to 
promote growth and metastasis of cancer cells (Liu et al. 2014).  
 
EZH2 
EZH2 is expressed in rapidly proliferating and developing tissue during embryogenesis. It is mainly 
found in undifferentiated cells (Ezhkova et al. 2009). An overexpression of EZH2 in differentiated 
cells will thus revert the cell back to rapid proliferation and other stem-like characteristics, which is 
favourable for the initiation of cancer. EZH2 has indeed been found to be overexpressed or mutated 
in a large variety of cancers, such as prostate, breast, bladder, endometrial cancer and melanoma. 
Deregulation of EZH2 also usually correlates with poor prognosis, aggressiveness, or advanced 
stages of the cancer (Dimou et al. 2017). 
In breast cancer, EZH2 levels correlate with the aggressiveness of the cancer, and EZH2 
overexpressing tumours are also more likely to metastasize (Kleer et al. 2003). In prostate cancer, 
the overexpression of both EZH2 mRNA and protein correlate with a poor prognosis, and EZH2 is 
the most upregulated gene in metastatic prostate cancer (Varambally et al. 2002). In addition to 
sporadic mutations in EZH2, the Polycomb machinery can also be directly engaged by an 
environmental carcinogen. For example, tobacco smoke activates the cancer stem cell maintenance 
machinery through the recruitment of EZH2 and SUZ12 and the hypermethylation of tumour 
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suppressor promoters (Hussain et al. 2009). Oestrogen is also an environmental signal that can 
repress EZH2 and reduce the H3K27me3 mark in chromatin, causing uterine leiomyomas 
(Greathouse et al. 2012).  
Abnormalities in EZH2 expression have been detected in different cancers. Various studies have also 
found an overexpression of EZH2 in non-small cell lung cancers. When testing for EZH2 in NSCLC 
tissue and normal tissue, EZH2 was found to be overexpressed in NSCLC tissue. This overexpression 
also correlated with poor prognosis. In addition, EZH2 was found to enhance cell growth and 
increase the progression of the cell cycle (Takawa et al. 2011). In another set of NSCLC tissue 
samples, squamous cell carcinoma showed higher expression of EZH2 than adenocarcinoma, and 
the expression of EZH2 in adenocarcinomas correlated with young age and smoking. NSCLC brain 
metastases were also found to have higher EZH2 than primary tumours. High EZH2 expression was 
found to predict aggressive tumour behaviour and rapid metastasis development (Behrens et al. 
2013). 
The effects of EZH2 overexpression have also been studied in a mouse model. The overexpression 
did not affect the mice during development, but the mice developed multiple different tumours in 
adulthood, including lymphoma, liver sarcoma and lung adenocarcinoma. An overall overexpression 
of EZH2 caused half of the mice to develop lung adenocarcinoma, and a targeted overexpression of 
EZH2 in the lung caused 42% of the mice to develop lung adenocarcinoma. EZH2 overexpressing 
tumours were also found to have decreased H3K27ac and increased H3K27me3, and a suppression 
of a set of EZH2 target genes was detected. This study also proposed an EZH2 inhibitor, which had 
anti-tumour activity (Zhang et al. 2016). Taking these results together, EZH2 could be used both as 
a diagnostic tool and a therapeutic target in NSCLC. 
The activity of EZH2 is mostly PRC2-dependent (Wassef et al. 2019). However, EZH2 overexpression 
cannot be treated as an increased activity of PRC2. There is some evidence of an independent role 
for EZH2. Solo EZH2 can act as a coactivator for other transcription factors and has been shown to 
have oncogenic function in prostate cancer (Xu et al. 2021). PRC2-independent EZH2 also acts in 
breast cancer by promoting cell proliferation (Shi et al. 2007) and activating or repressing 
transcription (Lee et al. 2011). However, these functions are not related to the H3K27me3 mark, but 
rather to H3K4me2 and H3K4me3 (Xu et al. 2012), implying that the target genes of solo EZH2 and 
PRC2-dependent EZH2 are most likely different.  
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The possible link between PRC2 and energy stress 
It has been proposed that an upstream regulator of PRC2 would be AMPK, which is a kinase that 
senses the energy status of the cell and responds to energy stress by being phosphorylated by LKB1. 
According to Wan et al. active AMPK would be able to phosphorylate the catalytic subunit EZH2. 
This phosphorylation would disrupt the connection between EZH2 and SUZ12, rendering the PRC2 
complex unable to catalyse the trimethylation of lysine 27 of histone 3. Genes normally repressed 
by this epigenetic mark would then be activated (Wan et al. 2018). If PRC2 is downstream of LKB1 
and AMPK, the activity of PRC2 would be changed according to the energy status of the cell, and the 
target genes of PRC2 would likely relate to metabolic pathways. 
 
AMPK 
AMP-dependent kinase (AMPK) is one of the main energy level sensors in the cell. It is usually found 
as a heterotrimeric protein complex, and its subunits are well conserved throughout all eukaryotes. 
AMPK is composed of the catalytic α-subunit and the regulatory β- and γ-subunits, all of which have 
paralogous genes expressing distinct isoforms of each of the subunits (AMPK-α1, -α2; -β1, -β2; -γ1, 
-γ2, -γ3, encoded by PRKAA1, PRKAA2; PRKAB1, PRKAB2; PRKAG1, PRKAG2, PRKAG3, respectively) 
(Hardie 2015). The different isoforms may change the function of the complex or have different 
subcellular locations. The isoforms of catalytic subunit are very similar yet have different substrate 
specificity and have a different phenotype as knockouts (Ross et al. 2016). 
AMPK functions by sensing changes in cellular AMP/ATP ratio, as the ratio rises during energy stress 
such as energy deprivation or exercise. When AMPK is activated by energy stress, it catalyses 
changes in the energy metabolism of the cell. AMPK senses the energy status of the cell with its γ-
subunits. They contain three binding sites for AMP, with ATP and ADP competitively binding to at 
least two of these sites. When the cell is under energy stress, less ATP and ADP is available, and the 
binding sites are occupied mainly by AMP (Hardie 2015). The binding of AMP induces a conformation 
change that makes AMPK a better substrate for liver kinase B1 (LKB1), the AMPK activating kinase, 
which then phosphorylates the Thr172 residue in the activation loop of the α subunit of AMPK 
(Young 2009). The binding of AMP also inhibits the dephosphorylation of AMPK Thr172 by protein 
phosphatases and activates AMPK by allosteric activation (Gowans et al. 2013). 
AMPK changes the metabolism of the cell when activated, and the activation requires the kinase 
activity of LKB1, which is upstream of AMPK. The specialty of this activation process is that LKB1 is 
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not affected by the energy status of the cell. This is important because it is an upstream kinase to 
multiple kinases with different functions. It is constitutively active, and the changing energy level 
has an impact on AMPK, not LKB1. This way AMPK is only phosphorylated when the conditions are 
right, even though LKB1 is always active (Lizcano et al. 2004). 
When activated, AMPK promotes catabolic pathways that produce ATP and inhibits anabolic 
pathways that require ATP. Catabolic pathways are, for example, glucose uptake and glycolysis, fatty 
acid uptake and synthesis and mitochondrial biogenesis. Anabolic pathways that are inhibited 
include fatty acid oxidation, rRNA synthesis, cellular growth, and division, which take up energy 
(Hardie et al. 2012). The role of AMPK is not limited to cellular level, as it also acts on systemic level. 
For example, AMPK increases food intake when expressed in the hypothalamus, increases fatty acid 
oxidation in skeletal muscle (Minokoshi et al. 2002) and suppresses gluconeogenesis in the liver 
(Yamauchi et al. 2002). 
Mechanistically, AMPK achieves these wide regulatory functions by phosphorylating a large variety 
of target proteins. Upon activation, AMPK phosphorylates TBC domain family member 1 (TBC1D1) 
and thioredoxin-interacting protein (TXNIP) to promote glucose uptake into the cell. AMPK also 
phosphorylates 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) to regulate 
glycolysis and phosphorylates cyclic-AMP-regulated transcriptional co-activator 2 (CRTC2) and class 
II histone deacetylases (HDACs) to inhibit the transcription of genes involved in gluconeogenesis. In 
addition, AMPK inhibits protein synthesis by inhibiting the mechanistic target of rapamycin complex 
1 (mTORC1), which functions in the activation of biosynthetic pathways such as protein translation 
and cell growth. Moreover, AMPK regulates mitochondrial processes such as mitophagy, 
mitochondrial fission, and mitochondrial biogenesis to enhance metabolic efficiency (Garcia et al. 
2017). AMPK is a kinase with many phosphorylation targets and important impacts on the energy 
metabolism of cells and tissues. Metabolic enzymes and metabolites can also regulate gene 
expression both directly and indirectly by activating or repressing other regulators. Therefore, AMPK 
can regulate gene expression through metabolic changes. Taking glucose metabolism as an 
example, it affects the expression of glycolytic and lipogenic enzymes, insulin, and glucose 




AMPK in cancer 
An abnormal metabolism is a hallmark of cancer. Cancer cells use aerobic glycolysis instead of 
oxidative phosphorylation. This is called the Warburg effect (Hanahan et al. 2000). In cancer cells, 
nutrient deprivation drives the metabolism of the cell towards the Warburg effect via a pathway 
that involves AMPK. This rescues the cells from apoptosis during nutrient deprivation (Wu et al. 
2013). Loss of AMPK has also been found to drive this switch from oxidative phosphorylation to 
aerobic glycolysis. The ability of AMPK to change the metabolism of the cell could be the mechanism 
through which AMPK carries out tumour suppressor functions. When AMPK is inactive, the 
metabolism of the cell shifts towards aerobic glycolysis, biomass accumulation and an increased 
amount of glucose carbons used in lipid synthesis. The pathways that are active when there is no or 
little AMPK in the cell enhance cell growth and proliferation, thus giving cancer cells a growth 
advantage (Faubert et al. 2013). In addition, AMPK has tumour suppressors both upstream and 
downstream in its signalling pathway. Well-known tumour suppressors include LKB1 upstream 
(Shaw et al. 2004) and TSC2 downstream of AMPK (Inoki et al. 2002). 
Surprisingly many cancer-driving mutations also have an impact on cell metabolism, suggesting that 
oncogenes and tumour suppressors are involved in metabolic pathways (Levine et al. 2010). The 
same mutations that give rise to cancer often also control the metabolism of the cancer cells, which 
is beneficial to the proliferation and growth of transformed cells (Shaw 2006).  
AMPK has indeed been found to be dysfunctional in breast cancer, where the signalling of AMPK 
phosphorylation was reduced (Hadad et al. 2009). The reduced expression of the gene that encodes 
AMPKα2 subunit (PRKAA2) was suggested to be a key modulator in the tumorigenesis of gastric 
cancer, as it was found to be differentially expressed, often mutated, and a target gene of key 
miRNAs (Kim et al. 2012). 
AMPK activity may also result in a pro-cancer situation. By changing the metabolism of the cell in 
nutrient-sparse situations, it helps the cells to adapt to such conditions and protects the cell from 
cellular stress due to energy deprivation. When AMPK functions normally and the cell encounters 
energy stress, AMPK blocks cellular growth and helps to activate alternative pathways for energy 
production (Shaw et al. 2004). Therefore, loss of AMPK may result in apoptosis under energy stress 
or hypoxic conditions (Faubert et al. 2013). Consequently, inhibition of AMPK combined with 
metabolic inhibitors could result in apoptosis, which could be explored as a therapeutic strategy for 
cancer. The same effect has been observed in LKB1 deficient tumour cells, which go into apoptosis 
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under energy stress conditions. The LKB1/AMPK signalling protects the cell against apoptosis when 
AMP levels are low (Shaw et al. 2004). Therefore, cancer treatment could benefit from the cancer 
cell’s dependence on AMPK in relation to energy stress. 
 
LKB1 
Liver kinase B1 (LKB1 or STK11) is a tumour suppressor that was initially discovered alongside the 
Peutz-Jeghers syndrome, caused by LKB1 mutations. These patients develop benign hamartomatous 
polyps in the gastrointestinal tract and are also at a very high risk of developing malignant tumours 
in multiple tissues. Sporadic mutations in LKB1 are behind 10-20% of PJS cases (Alessi et al. 2006) 
but are also found in one third of lung adenocarcinoma patients (Sanchez-Cespedes et al. 2002).  
In lung cancer, LKB1 is the third most commonly mutated gene after TP53 and KRAS (Blanco et al. 
2009). In non-small cell lung cancer, 80% of cell lines have loss of heterozygosity at the LKB1 locus 
in chromosome 19p (Virmani et al. 1998). Deletions in LKB1 have also been suggested to drive lung 
adenocarcinomas subtype switching to more aggressive squamous cell carcinomas (Zhang et al. 
2017). Alterations in LKB1 are more common in NSCLCs than SCLCs (Matsumoto et al. 2007) and are 
especially common in lung adenocarcinomas (Carretero et al. 2004). Some mutations in LKB1 
hamper its ability to phosphorylate substrates such as AMPK (Hawley et al. 2003), resulting in 
reduced ability of responding to energy stress. 
The possible link between AMPK and PRC2 would establish a pathway for LKB1 causing non-small 
cell lung cancer. An inactive LKB1 leads to AMPK inactivation. Without the phosphorylation of EZH2 
by AMPK, the PRC2 complex could stay active in all energetic situations, keeping target genes 
repressed in situations of energy stress. This could be the mechanism by which inactivating LKB1 
mutations lead to worse cases of non-small cell lung cancer.  
 
Target genes 
The target genes for this study were chosen from an RNA sequencing study performed in the 
laboratory of Tomi Mäkelä, where they were found to be induced by 2-deoxyglucose (2-DG) 
treatment in mouse embryonic fibroblasts and to be AMPK dependent (unpublished data). 2-DG is 
a glucose analogue and an inhibitor of glycolysis, taken up by the cell and phosphorylated by 
hexokinase in a manner similar to normal glucose, but the product 2-deoxyglucose-6-phosphate 
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cannot proceed into glycolysis. This causes a decrease in energy produced from glucose and the 
activation of AMPK, and results in energy stress. The gene expression data set resulting from the 
RNA sequencing study was discovered in a gene set enrichment analysis (GSEA) to resemble 
previously published data sets investigating PRC2 function and H3K27me3 marked chromatin. In 
addition, there is evidence in literature that they could be PRC2 targets. 
ATF3 
Activating transcription factor 3 (ATF3) is an adaptive-response gene and part of the ATF/cyclic AMP 
response element-binding transcription factor family. Its function is to adapt the cell to extra- and 
intracellular changes by activating or repressing gene expression. Due to its role in the regulation of 
cell cycle and apoptosis, ATF3 has been studied in relation to oncogenesis. Depending on the 
context, it seems to be able to act as both an oncogene and a tumour suppressor (Thompson et al. 
2009). There is evidence of ATF3 overexpression in human cancers, such as breast cancer (Yin et al. 
2008) and malignant prostate cancer with poor prognosis (Pelzer et al. 2006), but there is also 
evidence of ATF3 overexpression increasing apoptosis and reducing metastatic potential of human 
cancer cells in prostate cancer (Huang et al. 2008) and ovarian cancer (Syed et al. 2005).  
The link between ATF3 and lung cancer remains unclear. In one study, NSCLC cells were compared 
with normal bronchial epithelial cells, and an overexpression of ATF3 was found in the NSCLC cells 
(Song et al. 2012). However, in another study a downregulation of ATF3 was reported in lung cancer 
tissue specimens, and it correlated with metastasis (Jan et al. 2012). Evidence for ATF3 being a target 
of PRC2 also has not been studied much, but one study in T helper 15 cells found ATF3 to be a direct 
target of PRC2 (Escobar et al. 2014).  
KLF4 
Krüppel-like factor 4 (KLF4) is a transcription factor that regulates processes such as cell growth, 
proliferation, and differentiation (Ghaleb and Yang 2017). Therefore, it also plays a role in cancer, 
where its activity is regulated by hypermethylation of the KLF4 promoter (Cho et al. 2007) and 
histone methylation (Lindeman et al. 2010). In normal conditions, KLF4 suppresses apoptosis, but 
can switch its role to anti-apoptotic under certain conditions. KLF4 also has a dual role in cancer, as 
it has been found to function both as a tumour suppressor and an oncogene, depending on the cell 
and cancer types. This means that both less of KLF4 expression and overexpression of KLF4 have 
been found in cancers (Ghaleb and Yang 2017). This duality can be seen even within lung cancers, 
as KLF4 expression was decreased in non-small cell lung cancer but overexpressed in small-cell lung 
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cancer (Fadous-Khalifé et al. 2016). The lower expression levels of KLF4 in lung cancer were found 
to be both at protein and RNA level, and KLF4 was found to be methylated in more tumour tissues 
than normal tissues (Hofstetter et al. 2009). As hypermethylation is connected to transcriptional 
repression, KLF4 could be regulated in NSCLC through its methylation status.  
The role of KLF4 as an oncogene or as a tumour suppressor might be related to its subcellular 
localisation. Higher levels of KLF4 in the nucleus of a cell were linked to a worse prognosis for NSCLC 
patients, whereas higher levels in the cytoplasm correlated with better prognosis. These two were 
independent of each other (Liu et al. 2018).  
There is some evidence that EZH2 could be an upstream regulator of KLF4. In one study, the silencing 
of EZH2 was found to upregulate KLF4. EZH2 catalysing the formation of a silencing mark on the 
KLF4 promoter produced less KLF4. This was linked to poor prognosis in ovarian cancer (Zhang et al. 
2019). Considering these observations, downregulation of KLF4 in relation to non-small cell lung 
cancer could be worth researching.  
PIM1 
PIM1 is a serine/threonine kinase that participates in the regulation of cell survival, proliferation, 
and differentiation. It is a constitutively active kinase that can be phosphorylated for stability (Shah 
et al. 2008). PIM1 is a proto-oncogene that has a role in the tumorigenesis of different cancers, as 
it is overexpressed in prostate carcinomas (Valdman et al. 2004) and the chromosome region where 
Pim1 resides is often mutated in haematopoietic malignancies (Betts et al. 2008) and in non-small 
cell lung cancer (Kim et al. 2005). PIM1 is expressed in normal human cells, but its overexpression 
correlates with tumour aggressiveness and poor prognosis. A mutation in the PIM1 gene has been 
observed in NSCLCs, and it correlated with poor survival (Shah et al. 2008). Other studies also link 
higher expression of PIM1 to NSCLC by proposing that PIM1 could be involved in the tumorigenesis 
or the progression of non-small cell lung cancer (Jin et al. 2012) and that it could be a mediator of 
radioresistance in NSCLC (Kim et al. 2013).  
One proposition on how PIM1 could participate in tumorigenesis is metabolism. PIM1 was found to 
promote the Warburg effect in cancer cells, and it was upregulated in response to AMPK signalling. 
Phosphorylated AMPK and PIM1 expression increased correspondingly under glucose deprivation, 
and PIM1 expression was induced by AMPK activator A769662 treatment (Zhang et al. 2018). LKB1-
AMPK signalling could thus be a factor in the development of non-small cell lung cancer partly by 
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activating PIM1.  There is almost no evidence that PIM1 would be a target of PRC2.  One study found 
PRC2 binding to PIM1 RNA in mouse embryonic stem cells (Beltran et al. 2019). This is, however, not 
enough evidence that PRC2 would regulate the expression of PIM1.  
HES1 
Hairy and enhancer of split-1 (HES1) is a transcription factor that participates in physiological 
processes such as cell cycle and cellular differentiation, apoptosis, and self-renewal. Due to these 
properties, HES1 is also involved in cancer progression. It has been found to function in metastasis 
and tumour multidrug resistance (Liu Z.H. et al. 2015).  
HES1 has also been found to play a role in non-small cell lung cancer. HES1 overexpression was 
statistically associated with lower overall survival rate in both lung adenocarcinoma and lung 
squamous cell carcinoma. This association is likely due to Notch signalling, which is often higher in 
NSCLC and predicts poor prognosis. HES1 is a target of the Notch pathway, explaining why both are 
elevated in NSCLC (Yuan et al. 2015). 
Due to HES1 being a well-known direct transcriptional target of NOTCH1 (Palomero et al. 2006), a 
link between PRC2 and NOTCH1 most likely also links PRC2 and HES1 together. Indeed, in a study 
on in T cell acute lymphoblastic leukaemia, HES1 was upregulated in experiments where PRC2 
subunits EZH2 and SUZ12 were silenced. In addition, H3K27me3 levels were found to inversely 
correlate with HES1 expression (Ntziachristos et al. 2012). 
SOX2 
Sex determining region Y box 2 (SOX2) is a transcription factor well known for its stem cell 
properties, such as self-renewal and pluripotency. It also plays important roles in cell cycle control 
and DNA damage response. SOX2 is therefore also able to maintain stem cell-like properties in 
cancer cells. This has been studied in non-small cell lung cancer, where the overexpression of SOX2 
stimulates cell migration and anchorage-independent growth. In addition, when SOX2 was silenced 
in NSCLC cell lines, apoptosis was induced (Chen et al. 2013). A link of SOX2 to the progression of 
tumours in NSCLC has also been reported (Velcheti et al. 2013; Sholl et al. 2010). However, there 
have been conflicting findings about the overexpression of SOX2. Some studies show that 
upregulated SOX2 gene amplification correlated with poor prognosis (Sholl et al. 2010), whereas 
according to other studies, high levels of SOX2 would correlate with better prognosis (Velcheti et al. 
2013). In lung cancers, SOX2 has been found to be amplified in squamous cell carcinomas and linked 
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to poor prognosis in adenocarcinomas (Bass et al. 2009). There are also differences in the 
upregulation status of SOX2 in SCC and ADC, with it being more expressed in SCC (Chen et al. 2013).  
Some studies indicate that SOX2 and PRC2 could be related. The regulatory regions of SOX2 were 
found to be occupied by H3K27me3 and EZH2, which happened via the Calcium/calmodulin 
dependent protein kinase II alpha (CAMK2A). The suppression of CAMK2A increased EZH2 binding 
to the SOX2 regulatory regions and increased the H3K27me3 mark, leading to the reduced 
expression of SOX2 (Wang et al. 2020). In addition, other studies have suggested that SOX2 would 
collaborate with PRC2, co-occupying promoters of downstream developmental genes (Guo et al. 
2018). SOX2 has also been connected to LKB1 and AMPK. Loss of LKB1 and overexpression of SOX2 
are suggested to promote lung squamous cell carcinoma. Consistent with the fact that AMPK is a 
substrate of LKB1, an absence of phosphorylated AMPK was found in SOX2-LKB1 tumours 
(Mukhopadhyay et al. 2014).  
 
Aims of the study 
The aim of this project is to investigate the relationship between non-small cell lung cancer and the 
AMPK/PRC2 signalling axis during energy stress. This study aims to validate the mechanism of AMPK 
dependent transcriptional regulation by PRC2 and to identify genes regulated by the AMPK-PRC2 
signalling pathway in cellular energy stress.  
The study will strengthen the knowledge on mechanisms by which AMPK regulates metabolism 
during energy stress. EZH2 has been identified to be a potential target for anticancer therapy (Deb 
et al. 2014), but there is still very limited information of the cellular mechanisms of AMPK and PRC2. 
LKB1 mutations are common in NSCLC (Virmani et al. 1998), and finding a downstream mechanism 
linking AMPK and PRC2 together could help understand how LKB1 inactivation drives non-small cell 
lung cancer. Therefore, understanding how energy stress affects the activation of genes has clinical 
significance.  
Metabolism has an important effect on cancer, and their relationship is still not widely understood. 
By directing more research towards it, some interesting links and possibilities for therapeutical 
interventions might arise. Therefore, it is interesting to study the impact energy stress has on cancer 
cells, and try to unveil the mechanisms between LKB1, a well-known tumour suppressor, AMPK, an 





Picture 1. Graphical hypothesis.  
 
The hypothesis of the thesis is based on the possible mechanism for PRC2-mediated gene activation 
by AMPK during energy stress, described in the 2018 paper by Wan et al. The hypothesis is that 
energy stress activates AMPK, which then phosphorylates EZH2, inhibiting PRC2 and releasing its 
target genes from repression. However, the EZH2 T311A mutant cannot be phosphorylated by 
AMPK, and thus will leave PRC2 active in all energetic conditions. Therefore, cells with mutant EZH2 
will have more H3K27me3 during energy stress than their counterparts with wild type EZH2 
proteins. The hypothesis therefore predicts that cells with a wild type EZH2 and a mutant EZH2 will 
behave differently under energy stress, and this can be observed from histone methylation patterns 
and gene expression levels.  
This hypothesis of PRC2 being downstream of AMPK would also bring another point of view into 
mechanisms non-small cell lung cancer. Inactivation mutations in LKB1 are common in NSCLC, and 
they lead to AMPK inactivation, which in turn activates PRC2. With an abnormal methylation 
landscape, downstream tumour and differentiation suppressors lead to worse non-small cell lung 
cancer. Mutations in LKB1, AMPK and PRC2/EZH2 could therefore have similar effects on lung cancer 




The experimental design makes use of overexpression plasmids EZH2 wild type, EZH2 T311A mutant 
and GFP. These plasmids are used to make stable overexpression cell lines that can then be treated 
with 2-deoxyglucose to impose energy stress and study the epigenetic effects. The hypothesis was 
tested by using Western blotting to detect histone methylation patterns as well as the 
phosphorylation statuses of AMPK and its known target ACC, and RT-qPCR was used to measure the 
expression levels of selected target genes SOX2, ATF3, HES1, PIM1 and KLF4 in each situation. The 
results were compared between wild type EZH2 and mutant EZH2 under energy stress conditions.  
 
Experimental hypothesis 
The experimental hypothesis of the thesis is that the overexpression cell lines produce PRC2 
complexes containing the overexpressed EZH2 protein. The EZH2 T311A overexpression cell lines 
still have endogenous wild-type EZH2, but the assumption is that the mutant EZH2 proteins will be 
used in enough PRC2 complexes to see a change in histone modification and gene expression levels. 
According to the proposed mechanism, the EZH2 T311A mutant cells would behave more similarly 
when comparing energy stress and normal glucose conditions, whereas wild-type EZH2 
overexpression cells and GFP cells would have differences between the two energetic conditions. 
As for the results, the hypothesis suggests that a significant difference in gene activation of AMPK 
dependent genes will be observed during glucose deprivation when comparing EZH2 wild type and 
mutant overexpression cell lines. 
 
Materials and methods 
Cell culture 
In normal growing conditions, cells were grown in basal media supplemented with 10% foetal 
bovine serum (FBS; Gibco #10270-106), 2mM L-glutamine, penicillin (100U/ml) and streptomycin 
(100U/ml). When passaging, the cells were detached from plates using Trypsin-EDTA (0.05%, Gibco 
#25300054). PBS was used to rinse the cells. The condition in the cell culture incubator were 37°C 
and 5% CO2. 
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H358 cells are an immortalized cancer cell line derived from a minimally invasive lung 
adenocarcinoma (ATCC website). They were cultured in RPMI 1640 (without L-glutamine, Lonza #12-
167F) and above-mentioned supplements.  
Cell lines 2352.4 and 2352.9 are immortalized mouse embryonic fibroblasts (MEF), obtained from 
transgenic mice in our laboratory. In these cell lines, all AMPK alleles can be conditionally deleted; 
2352.4 is a homozygote with both alleles floxed (Prkaa1 flox/flox; Prkaa2 flox/flox) and 2352.9 is a 
heterozygote (Prkaa1 +/flox; Prkaa2 +/flox). These MEFs were cultured in Dulbecco’s Minimum 




The EZH2 wild type, EZH2 mutant are in N-terminal p-Flag CMV-2 expression vectors. The plasmids 
contain an ampicillin resistance gene, a flag tag, and a multiple cloning site. EZH2 wild type and EZH2 
T311A mutant plasmids were a gift from Li Xin Wan from Moffit Cancer Centre (Wan et al. 2018). In 
our laboratory, EZH2 wt and T311A mutant ORFs were cloned into pLenti lentiviral vectors. A GFP 
plasmid was used as control.  
Minipreps and midipreps of plasmids were prepared according to the protocol of the Macherey-
Nagel NucleoSpin plasmid DNA purification kit (Macherey-Nagel website). 
 
Virus transfection 
pLenti6.3-V5 overexpression lentiviruses were produced by transfecting HEK293FT cells with viral 
packaging and overexpression vectors. On day one, 6,000,000 cells were passaged on each 10cm 
plate, using DMEM without antibiotics (penicillin or streptomycin). The transfection was done on 
day two. Viral packaging vectors Delta8.9 and pLP-VSVG were co-transfected with one of the 
overexpression lentiviral vectors, pLenti6.3-emGFP, pLenti6.3-EZH2 wt or pLenti6.3-EZH2 T311A. 
The transfections were performed with Lipofectamine 2000 using manufacturer’s instructions. After 
4 hours, the transfection media was replaced with fresh DMEM + FBS + L-glutamine. The cells were 
incubated for 48 hours, and the virus supernatant was collected and passed through a 0.4um filter 




A 6-well plate passaged a few days prior was transduced with pLenti viruses EZH2 wt, EZH2 T311A 
and GFP. Two control wells were left without virus. The transduction media was prepared using 1ml 
of virus media from -70°C, 1ml of RPMI 1640 + all supplements + Polybrene infection/transfection 
reagent (Millipore TR-1003-G) 8ug/ml in final concentration. 2ml of transduction media were used 
per well. The next day, the media was changed to RPMI 1640 + all supplements. The day after this, 
the selection media containing 5ug/ml blasticidin was changed to all wells except the no virus no 
blasticidin control. From here on, the blasticidin selection was kept on the overexpression cell lines 
at all times. The overexpression cell lines were expanded and then frozen for upcoming 
experiments, and the control wells with blasticidin but no virus were monitored until dead. 
 
Western Blot 
Depending on the proteins to be detected, acrylamide gels were either cast by hand or precast 
gradient gels were used. For the detection of ACC, AMPK, and their phosphorylation status, 7% and 
10% gels were used. For the detection of H3 and H3K27me3, 4-20% precast gels (Mini-PROTEAN 
TGX Gels, 4-20%, 10-well comb, 50ul, BioRad #456-1094) were used. Vinculin or GAPDH were 
detected as loading controls on each blot. 
The samples were prepared according to their protein concentration, loading the same amount of 
protein into each well. The optimal amount of protein was 20ug in 20ul, but it was decreased when 
the concentration of the initial sample was not high enough. 20% of Laemmli loading dye was added, 
and the samples were boiled at 98°C for 5min before pipetting them into the gels. SDS-PAGE gels 
were run at 50V for 30min, then at 200V until the end of the gel was reached.  
After the gel was run, the proteins were blotted with the TurboBlotter machine, using the Trans-
Blot Turbo Transfer Pack (BioRad. #1704159). The gels were put onto membranes, and the machine 
was run for 10min with the BioRad protocol for midi gels. After the run was completed, the 
membrane was stained with Ponceau S dye (Sigma, P-7170) for 5 minutes to check for an even 
protein loading, then cut according to the ladder and visible proteins. The membrane was then 
blocked in 5% milk powder/BSA in 0.1% TBST (TBS, 0.1% Tween-20) for 1h. Milk powder was used 
for H3 and H3K27me3 and BSA for blots that included phosphorylated proteins (ACC, AMPK, p-ACC 
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and p-AMPK). After 1h of blocking, the membranes were put into primary antibodies, in rotation in 
the cold room overnight. See Table 1. for all antibodies. 
On the second day of the Western blot protocol, the membranes were washed 3 times for 10min in 
TBST. The membranes were incubated with secondary antibody dilutions (see antibody table) for 
1h in cold room rotation. The membranes were again washed 3 times for 10min in TBST, then 
imaged. The detection of the proteins was performed with Super Signal West Femto Maximum 
Sensitivity Substrate kit (Thermo Scientific, #34095), using 2ml of the diluted ECL reagents per 
membrane. 10% of Super Signal Femto reagents were diluted to 90% of TBS to get the working 
reagent. This was applied to the membrane, excess was poured off, and the membrane was imaged 
first with the chemiluminescence setting using ChemiDoc MP Imaging System (Bio-Rad), up to 60 
seconds for strong signal intensity and up to 10 minutes for weak intensity. The pictures were then 
processed on Microsoft PowerPoint. 
 
2-DG treatment 
6-well plates passaged at least one day before were used for the 2-DG treatment. Treatment medias 
were prepared as follows: No glucose DMEM + dialysed FBS + L-glutamine + penicillin-streptomycin 
as basal media. When indicated, 2-DG in powder form was added to 15mM final concentration, and 
1.11 M solution of glucose to get 25 mM final concentration. The old media was taken off of the 6-
well plates, the wells were rinsed with PBS and 2ml of the treatment media was added to each well. 
The plates were treated 20 minutes apart to allow the collection of both protein and RNA at exactly 
4h of the start of the treatment.  
 
Protein collection and preparation 
Protein samples were collected by aspirating the media from the wells, rinsing once with PBS, then 
pipetting 200ul of boiling hot LSB into each well. The wells were scraped with a cell scraper, then 
the samples were collected into Eppendorf tubes. The samples were boiled at 98°C for 5 minutes, 





To measure protein concentration, a Detergent-Compatible assay (Bio Rad) was done. Standard 
protein samples made from bovine serum albumin (BSA) and dissolved in LSB in the following 
concentrations: 0; 0,25; 0,5; 0,75; 1; 1,5; 2 mg / ml. Duplicates of both standard samples and samples 
to be tested were pipetted onto a 96-well plate. The DC assay was done according to the protocol 
from BioRad (BioRad website). 
 
RNA collection and extraction and measurement of RNA concentration 
RNA was collected using the Trizol protocol. The media was taken out of the cell culture wells, then 
Trizol reagent was added 1 ml per 6-well plate well. The wells were incubated for 5 min in room 
temperature, then collected into Eppendorf tubes. 200 ul of chloroform was added, the tubes were 
shaken and incubated 2 – 3 min, then centrifuged at 13 000 rpm for 15 min in 4 ˚C. The upper phase 
was taken into a new Eppendorf tube, and 500 ul of chloroform : isoamylalcohol (24:1) mixture was 
added. The mixture was centrifuged at 13 000 rpm 3 min, and the water phase was again taken into 
a new tube. 1 ul glycogen and 500 ul isopropanol were added, and the mixture was incubated for 
20 min on ice or overnight in -20 ˚C. The samples were centrifuged 13 000 rpm for 30 min at 9 ˚C, 
after which the tubes were taken on ice. The supernatant was removed, and the pellet was washed 
with 1 ml of 70 % ethanol and centrifuged for 5 min. The supernatant was removed, and the ethanol 
was left to evaporate with the lid open for about 10 min. The pellet was dissolved into 30 – 50 ul 
milliQ water by putting it into 65 ˚C, then on ice. The RNA samples were stored in -70 ˚C 
(Thermofisher website). 
RNA concentration was measured with the NanoDrop device.  
 
RT-qPCR 
cDNA was made from RNA samples by RT-PCR with Taqman Multiscribe reverse transcriptase 
reagents kit (Applied biosystems Life technologies; #N8080234). Samples were prepared to contain 
400ng of RNA in 7.6ul of milliQ water, and one noRT sample was added as a control. 0.75ul RQ1 
DNase Promega and 0,9ul 10x were added to each sample and they were incubated at 37°C for 
30min. 0,9ul Stop solution was added, followed by a 10min incubation at 65°C. Samples were put 
on ice, and 2ul 10X RT buffer, 0.3ul MgCl2 25mM, 4ul dNTP mix 2.5mM, 1ul Random primers 50uM, 
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0.5ul RNasin and 1,5ul milliQ water were added to each tube. 0.5ul MultiScribe reverse transcriptase 
was added to all samples except the noRT sample. The RT reaction was done as follows: 25°C for 
10min, 48°C for 30min, 95°C for 5min and lastly 15°C. The cDNA was stored in +4°C. 
For qPCR, the cDNA was diluted to get 10ng of cDNA in 1ul. qPCR was run in 96-well plates, and each 
well contained 1ul of cDNA, 0.8ul of primer mix with 5uM both forward and reverse primers, 10ul 
of KAPA SYBR FAST Universal 2X qPCR Master Mix (Sigma-Aldrich # KK4618) and 8,2ul of MilliQ 
water. The qPCR reaction was run with the StepOnePlus machine, using the StepOnePlus fast cycling 
protocol with a 3-minute initial denaturation step. 





Host  Information Dilution Diluted in Use 
H3 Rabbit Abcam Ab1791 1:10 000 5% milk Primary 
H3K27me3 Rabbit Millipore 07-449 1:1 000 5% milk Primary 
AMPK Rabbit CST#2532 1:500 5% BSA Primary 
p-AMPK Rabbit CST#2535 1:500 5% BSA Primary 
ACC Rabbit CST36662 1:250 5% BSA Primary 
p-ACC Rabbit CST#3661 1:500 5% BSA Primary 
Vinculin Mouse sigma V9131 1:30 000 5% milk Primary 
GAPDH Rabbit 14C10 CST#2118 1:9 000 5% BSA Primary 
V5 Mouse Invitrogen/Novex 
R96025, 46-0705 
1:1 000 5% BSA Primary 
Rabbit anti 
Mouse HRP 





Goat Millipore AP132P 1:5 000 5% milk / 
BSA 
Secondary 






H358 is a cancer cell line derived from a minimally invasive lung adenocarcinoma (ATCC website). It 
was chosen to study the AMPK-PRC2 pathway hypothesis in NSCLC cells. H358 was also chosen 
because of its LKB1 wild type status, a prerequisite for functional AMPK signalling. In addition, LKB1 
is often mutated in lung cancer, suggesting that LKB1 downstream substrates may play a role in 
carcinogenesis (Ji et al. 2007).  
H358 cells were transfected with pLenti plasmids EZH2 wild type (wt), EZH2 T311A mutant or GFP, 
and selected with blasticidin to obtain stable overexpression cell lines. The overexpression was 
confirmed with imaging of the GFP cell line and Western blot using V5 antibody for EZH2 wt and 
EZH2 mutant cell lines. Each cell line was then treated with 2-DG or glucose-containing media for 4 
hours, and RNA and protein were collected and analysed with RT-qPCR and Western blot, 
respectively. The H3K27me3 signal on whole cell level was also assessed on Western blot, and total 















Figure 1. A) Western blot showing the overexpression of V5 flag tag in the overexpression plasmid. 
The control sample consisted of lysate from a successful V5-tagged overexpression experiment and 
was included to control antibody function. The GFP plasmid is not V5 tagged due to stop codon 
preceding the C-terminal tag. Ponceau S staining is used as a loading control. EZH2 protein size is 
85kDa and GFP protein size is 28kDa. B) Microscope image showing the expression of GFP in the 
H358 cell line transfected with the GFP plasmid. Image taken with the EVOS microscope. C) Western 
blot for total ACC and AMPK. D) Western blot for phosphorylated ACC and AMPK. E) Western blot 
with the H358 overexpression cell lines EZH2 wt, EZH2 T311A and GFP each treated with 25mM 
glucose or 15mM 2-DG, detecting the total histone 3 in the cells. F) Western blot detecting the 
trimethylated lysine 27 of histone 3 in the different cell lines and treatments.  
The activity of AMPK was tested with Western blots using the antibodies against AMPK, ACC, and 
the phosphorylated forms p-AMPK and p-ACC. The blots showed that the total amount of AMPK and 
ACC stayed the same between the samples, but the phosphorylation status changed with energy 
stress. ACC was used to confirm normal AMPK activity, as it is a well-known phosphorylation target 
of AMPK (Dyck et al. 2001), and the phosphorylation of ACC under energy stress conditions was 
indeed very evident from the Western blots. AMPK also showed an increase in phosphorylation 
under energy stress with each cell line, which was as expected. The differences between the cell 
lines are in EZH2, and PRC2 is downstream of AMPK. Therefore, the activity of AMPK was not 
changed by the overexpression of the EZH2 and GFP plasmids.  
The total histone 3 Western blots were used to confirm that the amount of histone did not change 
between each sample. The H3K27me3 blots showed no significant difference in histone methylation 
between the samples. The hypothesis was that the methylation status of EZH2 wt and GFP cell lines 
would be lower during energy stress than with glucose, as energy stress activates AMPK and the 
PRC2 complex is unable to methylate H3K27. This is however not seen in the Western blots.  
The RNA collected from the same experiments as proteins was used to synthesise cDNA with reverse 























Figure 2. Gene expression levels as log2 fold changes from qPCR. Results for each sample were 
normalised to OAZ1. All results are compared to the glucose treated GFP sample. The results were 
obtained from three independent experiments. The plots were drawn with R and p-values were 
calculated with t-test. p-values are indicated as “ns” (non-significant) if over 0.05, * if P is less or 
equal to 0.05, ** if P is less or equal to 0.01 and *** if P is less or equal to 0.001. 
ATF3, PIM1, KLF4 and SOX2 show non-significant changes between glucose and 2-DG treated 
samples. There is a lot of variation between replicates and this prevents reaching the significance 
cutoff. Therefore, these genes do not seem to be reproducibly 2-DG responsive in H358 cells in these 
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experimental settings. HES1 gives statistically significant induction in 2-DG samples, but it is not 
EZH2 dependent, as the EZH2 T311A mutant cell line behaves in a similar way as the other 
overexpression cell lines. This would indicate that the mechanism by which HES1 is induced in 
response to 2-DG would be other than through the T311 phosphorylation site. 
 
Mouse Embryonic Fibroblasts 
To test the hypothesis in different cells, mouse embryonic fibroblasts (MEFs) were used to repeat 
the experiments. The cell line used was 2352.4, with both AMPK alleles floxed (Prkaa1 flox/flox; 
Prkaa2 flox/flox). Stable overexpression cell lines were made with the same EZH2 wt, EZH2 mutant and 
GFP plasmids as for H358, however, lentiviral particles were first produced and the plasmids were 
incorporated into the cells with lentiviral transduction, as these cells were not amenable to lipid-
mediated transfection. The overexpression was confirmed by microscope for GFP and by EZH2 
Western blot for EZH2 wt and EZH2 mutant. The overexpression of the wild type EZH2 was a little 















Figure 3. A) Western blot showing the overexpression of the 2352.4 overexpression cell lines. The 
antibody EZH2 detects both the wild type and T311A mutant EZH2s. Ponceau S staining is used as a 
loading control. B) Microscope image showing the expression of GFP in the MEF 2352.4 cell line 
containing the GFP plasmid. Image taken with the EVOS microscope. C) Western blot for total ACC 
and AMPK. D) Western blot for phosphorylated ACC and AMPK. E) Western blot with the MEF 2352.4 
overexpression cell lines EZH2 wt, EZH2 T311A and GFP each treated with 25mM glucose or 15mM 
2-DG, detecting the total histone 3 in the cells. F) Western blot detecting the trimethylated lysine 
27 of histone 3 in the different cell lines and treatments. 
After treating the overexpression cell lines with 2-DG or glucose, RNA and protein samples were 
collected. Protein samples were used for Western blotting, and antibodies were used to detect the 
effects on protein phosphorylation. ACC and AMPK both show slightly stronger signal with 2-DG 
when comparing phosphorylation statuses (Fig. 3).  This demonstrates that AMPK is activated by the 
2-DG treatment. ACC is a known LKB1 target (Dyck et al. 2001), and it is clearly phosphorylated 
during energy stress. There is no difference between the cell lines, and the mutation in EZH2 does 
not have an effect on the phosphorylation of ACC and AMPK. 
From the same samples, the H3K27me3 methylation status in whole cell lysate was investigated. 
The results show that the histone methylation status changes across the samples. The EZH2 T311A 
mutant samples have the strongest methylation signal, and EZH2 wt the weakest. EZH2 wt shows a 
very weak signal with both glucose and 2-DG, but EZH2 T311A has a slightly stronger signal with 
glucose than with 2-DG. According to the hypothesis, the methylation should decrease with energy 
stress in EZH2 wt and GFP but decrease less in EZH2 T311A. The Western blot does not support this 
hypothesis very clearly, as the basal levels of H3K27me3 are very low to start with in wt EZH2 
overexpressing cells.  
To test gene expression levels, the collected RNA was used to synthesise cDNA in with reverse 
transcription. The cDNA was then used to run qPCR, using primers for the genes Klf4, Atf3, Pim1, 
Hes1 and Sox2. The results were normalised to Oaz1. The 2-DG samples were then compared to the 
GFP glucose sample. Results show the gene expression fold changes for each overexpression cell 
line in glucose conditions and 2-DG conditions. The hypothesis was that expression of target genes 
in EZH2 T311A would be less induced than in EZH2 wt, which has the PRC2 complexes that are able 
to respond to energy stress and release target genes from repression. Atf3, Klf4 and Pim1 responded 




















Figure 4. qPCR results from RNA expression after 2-DG or glucose treatment in MEF overexpression 
cell lines. The values have been normalised to the housekeeping gene Oaz1 and compared to the 
glucose GFP sample. The results were obtained from 3 independent experiments, one of them with 
biological replicates. The plots were drawn with R and p-values were calculated with t-test. p-values 
are indicated as “ns” (non-significant) if over 0.05, * if P is less or equal to 0.05, ** if P is less or equal 
to 0.01 and *** if P is less or equal to 0.001. 
In Hes1 and Sox2, induction is not statistically significant, thus no reproducible gene expression 
changes can be detected. Therefore, 2-DG does not activate Hes1 and Sox2 in MEFs in this 
experimental setting. Klf4 and Atf3 show statistically significant induction with 2-DG but show very 
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similar patterns with all overexpression plasmids. This suggests that they are 2-DG responsive 
possibly through another pathway than EZH2. Pim1 shows statistically significant induction with 2-
DG, and the cell line overexpressing the mutant EZH2 responds differently from GFP and EZH2 wild 
type cell lines. In normal glucose conditions, the EZH2 T311A cell line has downregulated Pim1. The 
PRC2 complex carrying the mutant EZH2 cannot be phosphorylated and is thus constitutively active, 
so the genes that are PRC2 dependent are downregulated in comparison to wild type EZH2 
containing cells. Pim1 is likely 2-DG responsive through the T311 phosphorylation site.   
 
Discussion 
Lung cancer is among the most common cancers, but still has the worst prognosis. More people die 
of lung cancer than of breast, prostate, colorectal cancer, and leukaemia combined (Siegel et al. 
2019). There is an evident need for more understanding of the mechanisms behind lung cancer. 
PRC2 and its catalytic subunit EZH2 have been found to be overexpressed in non-small cell lung 
cancer, and mutations in their proposed upstream kinases LKB1 and AMPK are also tightly related 
to NSCLC. Therefore, the aim of this thesis was to test the proposed mechanism for PRC2 and AMPK 
during energy stress described by Wan et al. 2018, as well as to find potential targets for PRC2. The 
results suggest that Pim1 is a target of EZH2 in mouse embryonic fibroblasts and responds to 2-DG 
stimulation through the T311 site. The results also suggest that HES1 in H358 cells and Klf4 and Atf3 
in MEFs are 2-DG responsive, however, not through the T311 site.  
The study settings allowed to validate that the use of 2-DG put the cells into a state of energy stress. 
2-deoxyglucose is a glucose analog that lacks one hydroxyl group. It is taken into the cell through 
the same glucose transporters as glucose but is then converted to 2-deoxyglucose-6-phosphate 
(2DG-6P), which cannot be used in the next step of glycolysis to produce ATP. In addition, 2DG-6P 
accumulates into the cell, which inhibits the glycolysis enzyme hexokinase. Therefore, 2-DG 
establishes energy stress in two ways – by competing with glucose in glycolysis, without the 
production of ATP and by inhibiting the entry of glucose into glycolysis (Schmidt et al. 2020). In our 
study setting, cells treated with 2-DG also have no glucose in their media, making sure there is no 
ATP produced through glycolysis. The increased AMP/ATP ratio activates AMPK, which regulates the 
expression of genes involved in many pathways. The transcriptional changes that happen in the cells 
are most likely related to energy metabolism, switching from anabolic pathways to catabolic ones. 
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In this study, cells treated with 2-DG had elevated AMPK phosphorylation, implying that the 
LKB1/AMPK energy sensing axis worked in these settings. The phosphorylation status of ACC was 
also elevated, suggesting that activated AMPK was phosphorylating its downstream targets, as 
expected. This most likely has changed the transcription of other genes, as AMPK regulates glucose, 
lipid and protein metabolism when activated. If PRC2 is a direct target of AMPK during energy stress, 
it is probable that also EZH2 was phosphorylated in these conditions. There are many possible 
reasons why this would not have been visible in the histone methylation statuses.  
Assuming that the hypothesis of AMPK and PRC2 crosstalk is correct, energy stress conditions should 
change the methylation patterns of target gene promoters. However, no significant changes in 
methylation status were observed in Western blots detecting H3K27me3. One possible reason is 
that the samples used were whole cell lysate, and the H3K27me3 detected is from all areas of the 
genome, including regions that are not related to energy stress gene expression. H3K27me3 is 
located both at specific peaks and is spread over an entire locus, and three different enrichment 
profiles have been observed for H3K27me3. It is found on repressed genes, but also highly expressed 
ones, and around the transcription start site on bivalent genes, where it co-exists with H3K4me3 
(Young et al. 2011). The number of target genes that experience a change in methylation patterns 
due to energy stress might be so small, that their part in overall H3K27me3 is not detectable.  
As to why only one of the studied target genes followed the hypothesis, the reason might be in the 
experimental settings. The results rely on the assumption that the overexpressed mutant EZH2 
protein is incorporated into enough PRC2 complexes to have an impact big enough for it to affect 
histone methylation statuses and gene expression levels. These research settings do not prove that 
the mutant EZH2 gets incorporated into PRC2 complexes, although the results about Pim1 in MEFs 
would suggest that it does.  
The cell line overexpressing wild type EZH2 works as a control for what effects an overexpression of 
EZH2 could have. EZH2 is often overexpressed in cancers and correlates with poor prognosis, NSCLC 
included (Takawa et al. 2011), which leads to the question whether it could promote an increased 
activity of PRC2. However, no evidence was found in literature claiming that the overexpression of 
EZH2 would promote the overexpression of other PRC2 subunits. Rather, the overexpression of 
EZH2 is not considered to affect the methylation status of H3K27, as it requires the overexpression 
of other subunits as well (Conway et al. 2015). In addition, the results from Pim1 in MEFs would 
suggest that EZH2 is not a limiting factor. Comparing to the GFP overexpressing cell line treated with 
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glucose, the expression of Pim1 is not repressed in cells overexpressing EZH2 in glucose conditions. 
Furthermore, there is some evidence showing that the overexpression of EZH2 that is observed in 
multiple cancers correlates with other proliferation markers and could be a product of high 
proliferation of cancer cells, rather than a reason for it (Wassef et al. 2017). Therefore, 
overexpressing EZH2 wt is not expected change to the activity of PRC2 in the cell, but a difference 
in gene expression and methylation patterns is expected be seen with the expression of EZH2 T311A. 
To see a difference in the results, the EZH2 mutant should occupy enough PRC2 complexes to make 
the number of PRC2 complexes with endogenous wild type EZH2 significantly lower than in EZH2 wt 
and GFP overexpressing cells. 
Although the overexpression of EZH2 is not expected to change the activity of PRC2, the 
overexpression of EZH2 could, however, affect the cells in other ways. There is some evidence of 
EZH2 acting as an activator independently from the PRC2 complex (Xu et al. 2012; Lee et al. 2011; 
Shi et al. 2007). However, most of EZH2’s activity is connected to the PRC2 complex (Wassef et al. 
2019), and both histone 3 lysine 27 and the target genes studied in this thesis are linked to the 
repressive mark catalysed by the PRC2 complex, implying that solo EZH2 activity should not have an 
impact on the results. Nonetheless, there may be consequences for overexpressing EZH2 that are 
not taken into account in this study or even not known yet, such as the finding that overexpression 
of EZH2 promotes the formation of an previously unknown Polycomb complex, PRC4 (Kuzmichev et 
al. 2005). 
What must also be taken into account in these study settings is that although multiple repetitions 
of the experiments were done, there was only one of each overexpression cell lines. This raises the 
question of whether the properties seen in the results are due to the protein function or a 
characteristic of the specific pool of cells. Mutations could have happened during the process of 
making the overexpression cell lines and growing of the cells. However, due to the slow growth rate 
of the cells, it was not possible to shorten the time that they were in culture. The cells were not 
used past passage 18 counting from transduction.  
In conclusion, the results suggest that Pim1 could be a target gene of PRC2 in mouse embryonic 
fibroblasts, and that its activation during energy stress happens via the EZH2 T311 site. However, 
the overexpression of EZH2 wild type and mutant may not be enough to test the hypothesis, as 




More research would be needed to validate the hypothesis stated in this thesis. An interesting 
follow-up project would be to use MEF cell lines 2352.4 and 2352.9 and to delete the floxed AMPK 
alleles. The deletion of AMPK would allow to study how the cell reacts to energy stress when there 
is no AMPK. This way the hypothesis of the mechanism could be tested further, to see whether PRC2 
is only activated by AMPK during energy stress.  
In addition, studying the amounts of PRC2 subunits as free proteins and bound to other subunits 
could reveal information about the dynamics of the PRC2 complex. Identifying the possible limiting 
factor to the construction of more PRC2 complexes and finding out whether an overexpression of 
specific subunits trigger changes in the expression of other PRC2 subunits could increase the 
information about this epigenetic mechanism. Although EZH2 overexpression has been detected in 
multiple different cancers, the effect this overexpression has on the number of functional PRC2 
complexes and their activity is still not well understood. 
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